Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ABVC Biopharma Inc ABVC

Healthcare Biotechnology
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504... see more

Recent & Breaking News (NDAQ:ABVC)

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

GlobeNewswire October 26, 2023

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

GlobeNewswire October 17, 2023

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

GlobeNewswire October 9, 2023

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

GlobeNewswire August 23, 2023

ABVC Executes Cooperation Agreement for Strategic Investments

GlobeNewswire August 17, 2023

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

GlobeNewswire August 10, 2023

ABVC Corporate Update and CEO's Letter to Shareholders

GlobeNewswire August 7, 2023

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

GlobeNewswire August 3, 2023

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

GlobeNewswire August 1, 2023

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

GlobeNewswire July 31, 2023

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

GlobeNewswire July 27, 2023

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

GlobeNewswire July 26, 2023

ABVC BioPharma Announces Reverse Stock Split

GlobeNewswire July 24, 2023

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

GlobeNewswire July 6, 2023

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

GlobeNewswire June 26, 2023

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

GlobeNewswire June 20, 2023

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

GlobeNewswire June 12, 2023

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

GlobeNewswire June 6, 2023

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

GlobeNewswire May 22, 2023

ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder

GlobeNewswire May 4, 2023